Search results
FDA grants approval for two Eylea biosimilars for eye conditions
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe products aim to mitigate retinal damage and help maintain vision. The approved indications for...
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S....
WTRF Wheeling· 23 hours agoBiocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration ...
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 6 days agoThe success of the GLOW2 study is expected to serve as the basis for a regulatory filing for...
FDA approves 2 Eylea biosimilars
Becker’s Hospital Review· 2 days agoThe FDA granted approval to Biocon Biologics' drug Yesafili and Samsung Bioepis and Biogen's drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea, an injection made ...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 2 days agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Motley Fool via Yahoo Finance· 6 days agoExcluding its COVID-19 antibody, Regeneron's revenue increased by 7%. Eylea treats wet age-related ...
AGF Management Ltd. Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 6 days agoAGF Management Ltd. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the fourth quarter, according to its most recent Form 13F filing with ...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
WKRN Nashville· 7 days agoKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our ...
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 6.2%
ETF DAILY NEWS· 6 days agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling ...